Washington, Oct 14 (EFE) .- A panel of experts from the U.S. Food and Drug Administration (FDA) unanimously supported on Thursday recommending a booster dose of the Moderna vaccine in older people and at-risk population.
This is the same recommendation that this panel made at the time for the Pfizer vaccine, whose third dose was already authorized by the FDA at the end of September and is already being administered in these groups.
The same committee will debate friday's recommendation for a booster dose for Johnson & Johnson's vaccine.
Support for Moderna's booster dose has been unanimous for those over 65 years of age, adults at risk of suffering the disease severely due to their medical condition and workers who, due to their occupation, are more exposed to contagion.
Some 7 million Americans have received the third dose of COVID-19, including 3 million people in the past week, according to data released Wednesday by the White House pandemic response team.
The President of the United States, Joe Biden, expressed this morning his confidence that the FDA and the Centers for Disease Control (CDC) will end up approving the booster doses of Moderna and J & J, as they did with that of Pfizer, for those groups and calculated that such approval may arrive in the next two weeks.
In any case, he admitted that there are still 66 million Americans unvaccinated, a figure still "unacceptable."
